共 143 条
[1]
Marrero JA(2018)Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Hepatology 68 723-750
[2]
Kulik LM(2017)Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update Hepatol Int 11 317-370
[3]
Sirlin CB(1996)Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence Radiology 199 177-183
[4]
Omata M(1999)Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers Acad Radiol 6 282-291
[5]
Cheng AL(1998)Gadobenate dimeglumine (Gd-BOPTA). An overview Invest Radiol 33 798-809
[6]
Kokudo N(2002)Biliary imaging with Gd-EOB-DTPA: is a 20-minute delay sufficient? Acad Radiol 9 1322-1325
[7]
Reimer P(2002)Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid as an intrabiliary contrast agent: preliminary assessment AJR Am J Roentgenol 179 87-92
[8]
Rummeny EJ(1992)Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system Radiology 183 59-64
[9]
Shamsi K(1996)Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA Radiology 200 59-67
[10]
Spinazzi A(2000)Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study Radiology 215 727-736